618 related articles for article (PubMed ID: 25095501)
1. Clinical strategy for induction of transplantation tolerance through mixed chimerism.
Cosimi AB; Sachs DH; Sykes M; Kawai T
Clin Transpl; 2013; ():127-34. PubMed ID: 25095501
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical studies for transplant tolerance via the mixed chimerism approach.
Sasaki H; Oura T; Spitzer TR; Chen YB; Madsen JC; Allan J; Sachs DH; Cosimi AB; Kawai T
Hum Immunol; 2018 May; 79(5):258-265. PubMed ID: 29175110
[TBL] [Abstract][Full Text] [Related]
3. Inducing Transient Mixed Chimerism for Allograft Survival Without Maintenance Immunosuppression With Combined Kidney and Bone Marrow Transplantation: Protocol Optimization.
Lee KW; Park JB; Park H; Kwon Y; Lee JS; Kim KS; Chung YJ; Rhu JS; Choi S; Kwon GY; Kim HJ; Kang ES; Jung CW; Shin EC; Kawai T; Kim SJ; Joh JW
Transplantation; 2020 Jul; 104(7):1472-1482. PubMed ID: 31634324
[TBL] [Abstract][Full Text] [Related]
4. Tolerance induction: hematopoietic chimerism.
Kawai T; Sachs DH
Curr Opin Organ Transplant; 2013 Aug; 18(4):402-7. PubMed ID: 23838644
[TBL] [Abstract][Full Text] [Related]
5. Reflections on the unique tolerogenicity of bone marrow, the enigma of chimerism and clinical tolerance.
Monaco AP
Clin Transpl; 2013; ():157-66. PubMed ID: 25095504
[TBL] [Abstract][Full Text] [Related]
6. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic chimerism induces renal and skin allograft tolerance in DLA-identical dogs.
Tillson M; Niemeyer GP; Welch JA; Brawner W; Swaim SF; Rynders P; Lenz SD; Dean B; Lothrop CD
Exp Hematol; 2006 Dec; 34(12):1759-70. PubMed ID: 17157174
[TBL] [Abstract][Full Text] [Related]
8. Twenty-year Follow-up of Histocompatibility Leukocyte Antigen-matched Kidney and Bone Marrow Cotransplantation for Multiple Myeloma With End-stage Renal Disease: Lessons Learned.
Spitzer TR; Tolkoff-Rubin N; Cosimi AB; McAfee S; Dey BR; Chen YB; Delmonico F; Sykes M; Sachs DH; Kawai T
Transplantation; 2019 Nov; 103(11):2366-2372. PubMed ID: 30801529
[TBL] [Abstract][Full Text] [Related]
9. HLA identical non-chimeric and HLA disparate chimeric renal transplant tolerance.
Leventhal JR; Mathew JM; Ildstad S; Salomon DR; Kurian SM; Suthanthiran M; Tambur A; Friedewald J; Gallon L; Charette J; Levitsky J; Kanwar Y; Abecassis M; Miller J
Clin Transpl; 2013; ():145-56. PubMed ID: 25095503
[TBL] [Abstract][Full Text] [Related]
10. Immune monitoring of transplant patients in transient mixed chimerism tolerance trials.
Sykes M
Hum Immunol; 2018 May; 79(5):334-342. PubMed ID: 29289741
[TBL] [Abstract][Full Text] [Related]
11. Effect of Ex Vivo-Expanded Recipient Regulatory T Cells on Hematopoietic Chimerism and Kidney Allograft Tolerance Across MHC Barriers in Cynomolgus Macaques.
Duran-Struuck R; Sondermeijer HP; Bühler L; Alonso-Guallart P; Zitsman J; Kato Y; Wu A; McMurchy AN; Woodland D; Griesemer A; Martinez M; Boskovic S; Kawai T; Cosimi AB; Yang YG; Hu Z; Wuu CS; Slate A; Mapara M; Baker S; Tokarz R; D'Agati V; Hammer S; Pereira M; Lipkin WI; Wekerle T; Levings M; Sykes M
Transplantation; 2017 Feb; 101(2):274-283. PubMed ID: 27846155
[TBL] [Abstract][Full Text] [Related]
12. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
[TBL] [Abstract][Full Text] [Related]
13. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression.
Kawai T; Sachs DH; Sprangers B; Spitzer TR; Saidman SL; Zorn E; Tolkoff-Rubin N; Preffer F; Crisalli K; Gao B; Wong W; Morris H; LoCascio SA; Sayre P; Shonts B; Williams WW; Smith RN; Colvin RB; Sykes M; Cosimi AB
Am J Transplant; 2014 Jul; 14(7):1599-611. PubMed ID: 24903438
[TBL] [Abstract][Full Text] [Related]
14. Transient-mixed Chimerism With Nonmyeloablative Conditioning Does Not Induce Liver Allograft Tolerance in Nonhuman Primates.
Chaudhry S; Kato Y; Weiner J; Alonso-Guallart P; Baker S; Woodland DC; Lefkowitch JH; Duran-Struuck R; Sondermeijer HP; Zitsman J; Sears ML; Wu A; Karolewski B; Houck PJ; Martinez M; Kato T; Sykes M; Griesemer AD
Transplantation; 2020 Aug; 104(8):1580-1590. PubMed ID: 32732835
[TBL] [Abstract][Full Text] [Related]
15. Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation.
Hotta K; Oura T; Dehnadi A; Boskovic S; Matsunami M; Rosales I; Smith RN; Colvin RB; Cosimi AB; Kawai T
Transplantation; 2018 Apr; 102(4):e128-e136. PubMed ID: 29300231
[TBL] [Abstract][Full Text] [Related]
16. A clinically feasible approach to induce delayed tolerance in recipients of prior kidney or vascularized composite allotransplants.
Chen B; Xu H; Corbin DR; Ildstad ST
Transplantation; 2012 Oct; 94(7):671-8. PubMed ID: 22948444
[TBL] [Abstract][Full Text] [Related]
17. Preclinical and clinical studies on the induction of renal allograft tolerance through transient mixed chimerism.
Kawai T; Cosimi AB; Sachs DH
Curr Opin Organ Transplant; 2011 Aug; 16(4):366-71. PubMed ID: 21666482
[TBL] [Abstract][Full Text] [Related]
18. Renal allograft tolerance in DLA-identical and haploidentical dogs after nonmyeloablative conditioning and transient immunosuppression with cyclosporine and mycophenolate mofetil.
Niemeyer GP; Welch JA; Tillson M; Brawner W; Rynders P; Goodman S; Dufresne M; Dennis J; Lothrop CD
Transplant Proc; 2005 Dec; 37(10):4579-86. PubMed ID: 16387175
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Monitoring antidonor alloantibodies as a predictive assay for renal allograft tolerance/long-term observations in nonhuman primates.
Boskovic S; Kawai T; Smith RN; Wee SL; Nadazdin O; Koyama I; Saidman S; Cardarelli F; Elias N; Sykes M; Strom T; Colvin RB; Sachs DH; Cosimi AB
Transplantation; 2006 Sep; 82(6):819-25. PubMed ID: 17006330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
